CD4 and relapsing-remitting multiple sclerosis: To quantify the impact of NTZ and AHSCT on patient TCR repertoire, we performed TCRβ sequencing of T-cell subpopulations (naive and memory CD4+ and CD8+) isolated from PB of 15 RRMS patients before and after 24 months of NTZ or AHSCT treatment for a total of 160 sequenced repertoires.